<?xml version="1.0" encoding="UTF-8"?>
<p>Conventional inactivated vaccines fail to elicit broadly protective antibodies recognizing the HA stalk, as the dominant immune response in mice (Altman 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0003" ref-type="ref">2015</xref>) and humans (Ellebedy 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0026" ref-type="ref">2014</xref>) is directed against variable antigenic sites in the HA head. Development of strategies which shift the focus of the immune response toward conserved HA epitopes has thus become an important research objective (Krammer, 
 <xref rid="emmm201910938-bib-0047" ref-type="ref">2017</xref>). Toward this goal, sequential immunizations with different chimeric HA or headless HA were shown to trigger broadly reactive stalk antibodies (Impagliazzo 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0041" ref-type="ref">2015</xref>; Wohlbold 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0090" ref-type="ref">2015</xref>; Yassine 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0093" ref-type="ref">2015</xref>; Nachbagauer 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0063" ref-type="ref">2017</xref>). Other challenges associated with the vaccine manufacturing cycle including egg‐based production might, however, not be overcome by these candidate antigens (Impagliazzo 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0041" ref-type="ref">2015</xref>; Yassine 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0093" ref-type="ref">2015</xref>, Register ECT, 
 <xref rid="emmm201910938-bib-0071" ref-type="ref">2017</xref>). Thus, it has been appreciated that innovative delivery platforms such as viral vectors could be an important element on the quest for a universal and long‐lasting influenza vaccine (Erbelding 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0028" ref-type="ref">2018</xref>; Ortiz 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0068" ref-type="ref">2018</xref>). Commonly used viral vectors have proven their efficacy as influenza vaccine carriers in multiple studies (de Vries &amp; Rimmelzwaan, 
 <xref rid="emmm201910938-bib-0082" ref-type="ref">2016</xref>). However, most “traditional” vectors express viral gene products and/or induce strong inflammatory responses, causing safety concerns. Reports regarding genotoxicity have been limited to wild‐type AAV infection (Nault 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0065" ref-type="ref">2015</xref>), while AAV vectors show an advantageous safety profile (Buning &amp; Schmidt, 
 <xref rid="emmm201910938-bib-0017" ref-type="ref">2015</xref>). AAV vectors represent the first EMA‐ and FDA‐approved (FDA, 
 <xref rid="emmm201910938-bib-0029" ref-type="ref">2018</xref>) vector system for use in human gene therapy and were successfully used in preclinical active immunization studies against several infectious diseases (Nieto &amp; Salvetti, 
 <xref rid="emmm201910938-bib-0066" ref-type="ref">2014</xref>). Furthermore, AAV vectors can be produced in cell culture, stored at room temperature, and applied without needles into the nose, offering possible solutions to challenges regarding production and application of the current vaccine (Grimm &amp; Buning, 
 <xref rid="emmm201910938-bib-0034" ref-type="ref">2017</xref>).
</p>
